Ocumetics Technology Corp. (TSXV: OTC) (OTCQB: OTCFF) (FRA: 2QBO) announced that debentureholders have converted $1.4 million of principal into common shares at $0.32 per share, resulting in the issuance of 4,375,000 common shares. The conversion represents 35% of the Company’s previously outstanding debenture principal of $4 million, significantly strengthening the balance sheet as Ocumetics approaches key milestones in its patient study program.
“These debenture conversions reflect the confidence our investors and debenture holders continue to show in Ocumetics and our long-term vision,” said Dean Burns, President and CEO of Ocumetics. “We are actively managing our investments and stakeholder relationships as we continue to advance our patient study and focus on achieving the next major milestones for the Company.”
The conversion of debt into equity is expected to improve the Company’s financial flexibility and reduce ongoing interest costs while aligning investor interests with the continued advancement of Ocumetics’ technology platform and clinical development objectives. The Company continues to advance toward key regulatory milestones, including preparation for its planned Investigational Device Exemption (IDE) submission to the U.S. Food and Drug Administration.
Ocumetics is in the first-in-human early feasibility study phase of a game-changing technology for the ophthalmic industry. The Company has developed a dynamic intraocular lens that fits within the natural lens compartment of the eye, potentially eliminating the need for corrective lenses. It is designed to allow the eye’s natural muscle activity to shift focus from distance to near, providing clear vision at all distances without glasses or contact lenses, and without perceptible time lag.
The debt conversion marks a strategic move to strengthen the Company’s financial position ahead of these critical milestones. By reducing outstanding debt, Ocumetics lowers its interest obligations, freeing up capital for research and development. This financial restructuring also signals strong support from investors, which may enhance the Company’s ability to secure additional funding if needed.
As Ocumetics progresses toward its IDE submission, the strengthened balance sheet provides a solid foundation to navigate the regulatory process. The successful completion of patient studies and regulatory approvals could position Ocumetics as a leader in vision restoration technology, offering a transformative solution for millions of people worldwide who rely on corrective lenses.
For further information, interested parties can visit the Company’s profile on NewMediaWire. The original release is available on the same site.
